Boehringer Ingelheim International Gmbh

Remko Alexander Bakker

Frank Himmelsbach

Sara Frattini

Iain Lingard

Bernd Wellenzohn

Sarah Low

Peter Michael Benz

Sanjaya Singh

Riccardo Giovannini

Alexander Pautsch

Holger Rosenbrock

Michael Dziegelewski

Haiguang Xiao

Vladimir H Voynov

Sathyadevi Venkataramani

Sebastian Bandholtz

Dieter Hamprecht

Rolf Herrmann

Cynthia Hess Kenny

Heiko Friedrich Stahl

Matthias Eckhardt

Matthias Grauert

Elke Langkopf

Leo Thomas

Dieter Wolfgang Hamprecht

Holger Wagner

Thorsten Lehmann-Lintz

Justin M Scheer

Dieter Wiedenmayer

Peter Eickelmann

Steffen Breitfelder

Marc Grundl

Andreas Gollner

Thomas Fox

Frank Buettner

Joerg P Hehn

Wolfgang Rist

Giacomo Fossati

Kenji Egusa

Lore Florin

Fei Han

Kazutoshi Yokoyama

Sandeep Kumar

Joerg Rippmann

Lore Katharina Florin

Holger Fuchs

Takuma Katayama

Ngai Hang Victor Chong

This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.

Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases

The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.

Anti-TrkB antibodies

The present invention relates to compounds of general formula (I), wherein Dto D, -A-, n, R, R, Y, L andare defined as in claim, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema. 

Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.

Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof

Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R, Rand Rare as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

The present invention relates to compounds of general formula I, wherein Dto D, A, R, R, Y and n are defined as in claim, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema. 

The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and Rare as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity. 

Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists

Growing community of inventors

Biberach an der Riss, Germany

Remko Alexander Bakker